Safety Study of Multikine in the Treatment of Perianal Warts
Safety Study of Multikine in the Treatment of Perianal Warts
Caused by the human papillomavirus (HPV), anogenital warts are a common sexually-transmitted
 infection (STI). They are distressing to those who have them and are a source of viral
 shedding and transmission to others. Treatment of warts is aimed at destruction of the
 lesion.

 Objectives:

 1. Establish safety of Multikine in treatment of perianal condyloma.

 2. Describe presence of anal HPV and anal dysplasia in participants with perianal
 condyloma.

 3. Describe adverse effects associated with Multikine in the management of perianal
 condyloma.

 Design:

 Phase I, dose-escalation trial. Potential participants desiring treatment for their perianal
 warts will be referred to study by their primary clinician. All participants will undergo
 baseline anal Pap, anal HPV subtyping, perianal condyloma characterization (count,
 measurement, photography), and complete a baseline questionnaire. Cohort A participants will
 undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14
 days, off for 14 days, then again once daily, Monday through Friday for 14 days. If no
 serious adverse events are noted after 4 weeks of therapy, cohort B will be studied using the
 same schedule but with a dose of 400IU per treatment. Each participant will undergo anal Pap
 and anal HPV subtyping once weekly during treatment. Condyloma characterization (count,
 measurement, photography) will occur prior to each treatment. After treatment completed,
 participants will complete a follow-up visit at 70, 100, 130, 160 days and have anal Pap,
 anal HPV subtyping, and perianal condyloma characterization (count, measurement, photography)
 performed.

 Subjects:

 The study will be open to adult men and women who are HIV-infected who receive medical care
 from the Naval Medical Center San Diego.

 Main Outcome Measures:

 1. Perianal wart characterization [count, measurement (in millimeters diameter)],
 photography)

 2. HPV subtype in anal canal

 3. Anal dysplasia cytologic grade

 4. Questionnaire responses

 5. Adverse effects experienced during treatment, recorded in symptom log
There are no further details to describe regarding this research project
Inclusion Criteria:

 -  ≥18 years of age

 -  Diagnosed with perianal condyloma by primary clinician

 -  HIV-infected, may be on or off of antiretroviral therapy

 -  any CD4 count will be considered appropriate for study

 -  Blood WBC > 2.0x103/mm3 and absolute neutrophils count > 500

 -  Blood hemoglobin > 10.0 g/dL

 -  Blood platelet count > 50x103/mm3

 -  Serum total bilirubin < 6.0 mg/dL (participants taking atazanavir-based ARV regimens
 may have elevated total bilirubin but are generally < 6)

 -  Blood aspartate aminotransferase (AST) < 100 U/L (<2 ULN)

 -  Blood alanine aminotransferase (ALT) < 130 U/L (<2 ULN)

 -  Serum creatinine < 1.5 mg/dL

 -  ECOG performance status < 3

 -  If a subject is of reproductive potential he/she and her/his sexual partner MUST be
 willing and able to utilize effective methods of contraception (e.g., birth control
 pill, barrier methods with spermicide - as applicable) for the duration of the study
 including the study follow-up period.

 Exclusion Criteria:

 -  Anal cancer (current or history of)

 -  Inability to attend study visits

 -  Participation in any other drug study

 -  History of asthma

 -  History of organ transplantation or requiring chronic administration of immune
 suppressive drugs in the last 6 months

 -  For women, neither pregnant nor lactating

 -  In the opinion of the PI, the subject may not be able to tolerate the study treatment
 regimen